## ICMJE DISCLOSURE FORM

Date: 6/11/2021 Your Name: Neil Stahl

Manuscript Name: Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None			
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	Regeneron Pharmaceuticals Inc.	Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments (Licensed and royalties. Licensee: Roche Assigned to: Regeneron Pharmaceuticals, Inc.)		
4	Consulting fees	None			

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	,		
7	Support for attending	None	
,	meetings and/or travel	140112	
	meetings and, or traver		
8	Patents planned, issued or	Regeneron	US10787501: Anti-SARS-CoV-2-Spike Glycoprotein
	pending	Pharmaceuticals, Inc.	Antibodies and Antigen-Binding Fragments (Issued
			Patent. Assigned to Regeneron Pharmaceuticals, Inc.)
		Regeneron	US10954289: Anti-SARS-CoV-2-Spike Glycoprotein
		Pharmaceuticals, Inc.	Antibodies and Antigen-Binding Fragments (Issued
			Patent. Assigned to Regeneron Pharmaceuticals, Inc.)
		Regeneron	US10975139: Anti-SARS-CoV-2-Spike Glycoprotein
		Pharmaceuticals, Inc.	Antibodies and Antigen-Binding Fragments (Issued
			Patent. Assigned to Regeneron Pharmaceuticals, Inc.)
		Regeneron	Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and
		Pharmaceuticals, Inc.	Antigen-Binding Fragments (Pending Patent. Assigned to
			Regeneron Pharmaceuticals, Inc.)
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Regeneron	Stock ownership/stock options
		Pharmaceuticals, Inc.	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Regeneron	Current employee
	financial interests	Pharmaceuticals, Inc.	

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.